Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginsentide TP1 is a 31-residue, cysteine- and glycine-rich microprotein derived from *Panax ginseng*. It belongs to a novel family of heat-stable, proteolysis-resistant, and cell-penetrating peptides characterized by an eight-cysteine motif and a unique disulfide connectivity that forms a compact, pseudocyclic structure. Ginsentide TP1 exhibits potent cardioprotective and vasoprotective properties by mitigating oxidative stress, endoplasmic reticulum (ER) stress, and mitochondrial dysfunction. In preclinical models, it has demonstrated the ability to protect against doxorubicin-induced cardiotoxicity and hypoxia-induced vascular endothelial dysfunction without compromising the efficacy of chemotherapeutic agents. Its mechanism involves the restoration of nitric oxide (NO) signaling and the reduction of pro-inflammatory and apoptotic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginsentide TP1.